Heska Corporation (HSKA) Receives $106.40 Consensus PT from Brokerages

Heska Corporation (NASDAQ:HSKA) has been assigned an average recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $106.40.

Several research analysts recently issued reports on the company. B. Riley reissued a “neutral” rating and issued a $96.50 price objective on shares of Heska Corporation in a research note on Thursday, August 3rd. BidaskClub raised Heska Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Benchmark Co. reissued a “buy” rating and issued a $120.00 price objective (up previously from $106.00) on shares of Heska Corporation in a research note on Wednesday, August 9th. Zacks Investment Research cut Heska Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Aegis increased their price objective on Heska Corporation from $114.50 to $129.50 and gave the stock a “buy” rating in a research note on Tuesday, August 1st.

In other Heska Corporation news, CFO John Mcmahon sold 2,608 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total transaction of $263,851.36. Following the sale, the chief financial officer now owns 193 shares of the company’s stock, valued at approximately $19,525.81. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nancy Wisnewski sold 825 shares of the stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $102.21, for a total value of $84,323.25. Following the sale, the executive vice president now directly owns 38,114 shares in the company, valued at approximately $3,895,631.94. The disclosure for this sale can be found here. 14.70% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Albion Financial Group UT boosted its position in Heska Corporation by 1.3% during the 2nd quarter. Albion Financial Group UT now owns 6,421 shares of the medical research company’s stock valued at $655,000 after acquiring an additional 80 shares in the last quarter. Susquehanna International Group LLP bought a new stake in Heska Corporation during the 2nd quarter valued at $854,000. The Manufacturers Life Insurance Company boosted its position in Heska Corporation by 6.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,112 shares of the medical research company’s stock valued at $522,000 after acquiring an additional 294 shares in the last quarter. State Street Corp boosted its position in Heska Corporation by 12.7% during the 2nd quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock valued at $19,998,000 after acquiring an additional 22,053 shares in the last quarter. Finally, Fred Alger Management Inc. boosted its position in Heska Corporation by 133.8% during the 2nd quarter. Fred Alger Management Inc. now owns 97,229 shares of the medical research company’s stock valued at $9,924,000 after acquiring an additional 55,647 shares in the last quarter. 81.36% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Heska Corporation (HSKA) Receives $106.40 Consensus PT from Brokerages” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/26/heska-corporation-hska-receives-106-40-consensus-pt-from-brokerages.html.

Heska Corporation (NASDAQ HSKA) traded down 0.716% during trading on Thursday, reaching $96.405. The company had a trading volume of 24,333 shares. The company has a market capitalization of $696.62 million, a PE ratio of 49.136 and a beta of 0.85. The firm’s 50 day moving average is $94.36 and its 200 day moving average is $98.36. Heska Corporation has a one year low of $46.51 and a one year high of $115.00.

Heska Corporation (NASDAQ:HSKA) last announced its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Heska Corporation had a return on equity of 15.87% and a net margin of 10.70%. The company had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same quarter in the prior year, the firm earned $0.35 earnings per share. Heska Corporation’s revenue was up 14.3% compared to the same quarter last year. On average, equities research analysts predict that Heska Corporation will post $2.04 earnings per share for the current year.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply